Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma

Lucía Trilla-Fuertesa, Ismael Ghanemb, Joan Maurelc, Laura G-Pastriánd,e, Marta Mendiolaef, Cristina Peñad, Rocío López-Vacasg, Guillermo Prado-Vázquez, Elena López-Camachog, Andrea Zapater-Moros, Victoria Herediai,h, Miriam Cuatrecasas, Pilar García-Alfonsoj, Jaume Capdevila, Carles Conill, Rocío López-Vacasg, Guillermo Prado-Vázqueza, Elena López-Camachog, Andrea Zapater-Moros, Angelo Gámez-Pozog, Jaime Feliu, Juan Ángel Fresno Vara

ABSTRACT

Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. We analyzed 46 paraffin-embedded tumor samples from patients diagnosed with primary ASCC by exome sequencing. A bioinformatics approach focused in the identification of high-impact genetic variants, which may act as drivers of oncogenesis, was performed. The relation between genetics variants and prognosis was also studied. The list of high-impact genetic variants was unique for each patient. However, the pathways in which these genes are involved are well-known hallmarks of cancer, such as angiogenesis or immune pathways. Additionally, we determined that genetic variants in BRCA2, ZNF750, FAM208B, ZNF599, and ZC3H13 genes are related with poor disease-free survival in ASCC. This may help to stratify the patient’s prognosis and open new avenues for potential therapeutic intervention. In conclusion, sequencing of ASCC clinical samples appears an encouraging tool for the molecular portrait of this disease.

Introduction

Anal squamous cell carcinoma (ASCC) is a rare tumor. In 2019, an estimated 8300 new cases will occur in the United States, representing approximately 2.5% of all gastrointestinal cancers [1]. Since the 1970s, the standard treatment has consisted of a combination of 5-fluorouracil (5FU) with mitomycin C or cisplatin and radiotherapy [2,3]. Despite this treatment being very effective for early-stage tumors, the disease-free survival (DFS) rate in T3-T4 or N+ tumors ranges between 40% and 70% [4,5]. Patients diagnosed with ASCC do not benefit from